Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers
CONCLUSION: RDT has the potential to restore RAI avidity and induce RECIST responses following I-131 therapy in select patients with RAIR-DTC, particularly those with RAS-driven 'follicular' phenotypes. In patients with PTC, none of the evaluated clinical outcomes differed statistically between the redifferentiated and non-redifferentiated subgroups. Further studies are needed to better characterize the long-term survival and/or safety outcomes of high-dose RAI following RDT, particularly whether it could be associated with histologic anaplastic transformation.PMID:37917101 | DOI:10.1089/thy.2023.0456
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Authors: David Toro-Tobon John C Morris Crystal R Hilger Candy Peskey Jolanta M Durski Mabel Ryder Source Type: research
More News: Cancer | Cancer & Oncology | Endocrinology | Iodine | Statistics | Study | Thyroid | Thyroid Cancer